NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,175 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $3.52, for a total value of $21,736.00. Following the transaction, the chief operating officer now directly owns 89,690 shares in the company, valued at $315,708.80. The sale was disclosed in a filing with the SEC, which is available through this link.
Ronald Allen Louks also recently made the following trade(s):
- On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The shares were sold at an average price of $3.03, for a total value of $15,892.35.
- On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The shares were sold at an average price of $3.39, for a total value of $22,729.95.
NantHealth Inc (NH) traded up $0.01 during trading on Friday, reaching $3.76. The company’s stock had a trading volume of 131,900 shares, compared to its average volume of 191,137. NantHealth Inc has a twelve month low of $2.60 and a twelve month high of $10.19. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93. The stock has a market cap of $407.32 and a P/E ratio of -2.58.
NH has been the topic of several research analyst reports. Zacks Investment Research downgraded NantHealth from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. BidaskClub downgraded NantHealth from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. Canaccord Genuity dropped their price target on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. Finally, Jefferies Group reiterated a “buy” rating and set a $5.00 price target on shares of NantHealth in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $8.05.
Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of NantHealth by 91.5% in the second quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after buying an additional 81,024 shares during the last quarter. GSA Capital Partners LLP boosted its position in NantHealth by 154.7% during the third quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock worth $299,000 after purchasing an additional 44,100 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in NantHealth by 136.9% during the second quarter. TIAA CREF Investment Management LLC now owns 47,848 shares of the company’s stock worth $202,000 after purchasing an additional 27,648 shares in the last quarter. National Planning Corp boosted its position in NantHealth by 21.1% during the third quarter. National Planning Corp now owns 138,700 shares of the company’s stock worth $656,000 after purchasing an additional 24,200 shares in the last quarter. Finally, Highbridge Capital Management LLC boosted its position in NantHealth by 6.5% during the third quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock worth $1,030,000 after purchasing an additional 15,264 shares in the last quarter. Hedge funds and other institutional investors own 7.10% of the company’s stock.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.